News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
191,057 Results
Type
Article (4941)
Company Profile (56)
Press Release (186055)
Multimedia
Podcasts (5)
Webinars (7)
Section
Business (52903)
Career Advice (298)
Deals (10816)
Drug Delivery (21)
Drug Development (8901)
Employer Resources (28)
FDA (5204)
Job Trends (4550)
News (79952)
Policy (6005)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (605)
Accelerated approval (3)
Allergies (40)
Alliances (18732)
ALS (29)
Alzheimer's disease (338)
Antibody-drug conjugate (ADC) (41)
Approvals (5382)
Artificial intelligence (296)
Autoimmune disease (23)
Automation (30)
Bankruptcy (67)
Best Places to Work (4174)
BIOSECURE Act (3)
Biosimilars (59)
Biotechnology (41)
Bladder cancer (46)
Brain cancer (11)
Breast cancer (129)
Cancer (967)
Cardiovascular disease (74)
Career advice (268)
Career pathing (10)
CAR-T (39)
CDC (1)
Cell therapy (146)
Cervical cancer (12)
Clinical research (7922)
Collaboration (760)
Compensation (121)
Complete response letters (7)
COVID-19 (518)
CRISPR (35)
C-suite (239)
Cystic fibrosis (10)
Data (1196)
Decentralized trials (2)
Denatured (5)
Depression (29)
Diabetes (110)
Diagnostics (3279)
Digital health (31)
Diversity (5)
Diversity, equity & inclusion (13)
Drug discovery (85)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (13)
Earnings (17672)
Editorial (5)
Employer resources (28)
Events (24761)
Executive appointments (344)
FDA (6292)
Funding (509)
Gene editing (51)
Generative AI (19)
Gene therapy (122)
GLP-1 (158)
Government (754)
Grass and pollen (2)
Guidances (158)
Healthcare (6089)
HIV (29)
Huntington's disease (1)
IgA nephropathy (6)
Immunology and inflammation (14)
Immuno-oncology (9)
Indications (38)
Infectious disease (585)
Inflammatory bowel disease (38)
Inflation Reduction Act (2)
Influenza (31)
Intellectual property (62)
Interviews (39)
IPO (4396)
IRA (5)
Job creations (532)
Job search strategy (214)
JPM (6)
Kidney cancer (1)
Labor market (15)
Layoffs (47)
Leadership (9)
Legal (1063)
Liver cancer (10)
Longevity (5)
Lung cancer (123)
Lymphoma (60)
Machine learning (22)
Management (13)
Manufacturing (353)
MASH (14)
Medical device (7280)
Medtech (7313)
Mergers & acquisitions (6903)
Metabolic disorders (208)
Multiple sclerosis (27)
Neurodegenerative disease (59)
Neuropsychiatric disorders (8)
Neuroscience (567)
NextGen: Class of 2026 (2441)
Non-profit (1051)
Now hiring (8)
Obesity (75)
Opinion (124)
Ovarian cancer (24)
Pain (85)
Pancreatic cancer (44)
Parkinson's disease (61)
Partnered (17)
Patents (135)
Patient recruitment (111)
Peanut (17)
People (14652)
Pharmaceutical (9)
Pharmacy benefit managers (8)
Phase 1 (1891)
Phase 2 (3039)
Phase 3 (3424)
Pipeline (1403)
Policy (30)
Postmarket research (360)
Preclinical (860)
Press Release (19)
Prostate cancer (56)
Psychedelics (4)
Radiopharmaceuticals (73)
Rare diseases (143)
Real estate (1772)
Recruiting (8)
Regulatory (5311)
Reports (13)
Research institute (633)
Resumes & cover letters (47)
Rett syndrome (7)
RNA editing (3)
RSV (14)
Schizophrenia (14)
Series A (84)
Series B (65)
Service/supplier (6)
Sickle cell disease (9)
Special edition (1)
Spinal muscular atrophy (16)
Sponsored (23)
Startups (844)
State (1)
Supply chain (50)
Tariffs (6)
Vaccines (172)
Venture capital (12)
Weight loss (45)
Women's health (42)
Worklife (4)
Date
Today (21)
Last 7 days (180)
Last 30 days (732)
Last 365 days (8234)
2026 (848)
2025 (8493)
2024 (10398)
2023 (11476)
2022 (17340)
2021 (18516)
2020 (18658)
2019 (16549)
2018 (11897)
2017 (9304)
2016 (8740)
2015 (9651)
2014 (7049)
2013 (6030)
2012 (6382)
2011 (6116)
2010 (4895)
Location
Africa (183)
Alabama (22)
Alaska (2)
Arizona (89)
Arkansas (4)
Asia (9958)
Australia (1214)
California (2841)
Canada (925)
China (245)
Colorado (195)
Connecticut (110)
Delaware (126)
Europe (25963)
Florida (499)
Georgia (167)
Hawaii (2)
Idaho (43)
Illinois (408)
India (38)
Indiana (323)
Iowa (9)
Japan (121)
Kansas (35)
Kentucky (13)
Louisiana (9)
Maine (29)
Maryland (323)
Massachusetts (1568)
Michigan (173)
Minnesota (326)
Mississippi (5)
Missouri (74)
Montana (19)
Nebraska (12)
Nevada (41)
New Hampshire (49)
New Jersey (946)
New Mexico (17)
New York (611)
North Carolina (616)
North Dakota (8)
Northern California (1272)
Ohio (151)
Oklahoma (10)
Oregon (17)
Pennsylvania (622)
Puerto Rico (4)
Rhode Island (25)
South America (326)
South Carolina (51)
South Dakota (1)
Southern California (1100)
Tennessee (63)
Texas (476)
United States (11197)
Utah (101)
Vermont (1)
Virginia (75)
Washington D.C. (20)
Washington State (172)
West Virginia (2)
Wisconsin (89)
Wyoming (1)
191,057 Results for "bbi solutions".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
January 20, 2026
·
6 min read
Drug Development
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
Boundless Bio today announced that the first patient has been dosed with BBI-825 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic cancer with resistance gene amplifications (NCT06299761).
April 11, 2024
·
7 min read
Biotech Beach
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
Boundless Bio presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.
April 8, 2024
·
8 min read
Press Releases
Agilent Showcases Next‑Generation Automated Solutions at SLAS2026
February 5, 2026
·
4 min read
Press Releases
Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
February 3, 2026
·
5 min read
Drug Development
Bond Biosciences Announces Positive Phase Ia/b Pharmacodynamic and Safety Data for BBI-001, a Novel, Non-Absorbed, Oral Therapy for Iron Overload
BBI-001 was well tolerated with no dose limiting toxicities. Single-dose administration demonstrated a statistically significant reduction of dietary iron absorption.
July 20, 2023
·
3 min read
Business
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI ® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors.
September 18, 2023
·
4 min read
Press Releases
HighLife Receives CE Mark Approval for its TMVR Solution
January 26, 2026
·
4 min read
Sponsored
Accelerating Timelines and Reducing Cost in Early Clinical Drug Development With ICON’s Accelerated Pharmaceutical Solutions
Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced formulation design, real-time dose flexibility, and cutting-edge CMC expertise to transform complexity into clarity. By uniting science, technology, and strategy, biotechs can move faster, smarter, and with confidence—turning obstacles into opportunities for breakthrough success.
December 8, 2025
·
5 min read
·
Arjen Akkerman
Business
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO ® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors.
September 19, 2023
·
4 min read
1 of 19,106
Next
